You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxaprozin
Accession NumberDB00991  (APRD00030)
TypeSmall Molecule
GroupsApproved
Description

Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

Structure
Thumb
Synonyms
Danoprox
Daypro
Dayrun
Deflam
Duraprox
Oxaprozina
Oxaprozine
Oxaprozinum
Walix
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dayprotablet, film coated600 mg/1oralG.D. Searle LLC Division of Pfizer Inc1992-10-29Not applicableUs
Dayprotablet600 mgoralPfizer Canada Inc1997-01-072012-09-20Canada
Dayprotablet, film coated600 mg/1oralPd Rx Pharmaceuticals, Inc.1992-10-29Not applicableUs
Oxaprozintablet, film coated600 mg/1oralGreenstone LLC2013-03-28Not applicableUs
Rhoxal-oxaprozintablet600 mgoralRhoxalpharma Inc2001-06-112009-11-24Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxaprozintablet600 mgoralApotex Inc2001-05-29Not applicableCanada
Oxaprozintablet, film coated600 mg/1oralApotex Corp.2004-09-03Not applicableUs
Oxaprozintablet, film coated600 mg/1oralbryant ranch prepack2010-09-08Not applicableUs
Oxaprozintablet, film coated600 mg/1oralTeva Pharmaceuticals USA Inc2003-05-12Not applicableUs
Oxaprozintablet, film coated600 mg/1oralUnit Dose Services2010-09-08Not applicableUs
Oxaprozintablet, film coated600 mg/1oralClinical Solutions Wholesale2001-01-31Not applicableUs
Oxaprozintablet, film coated600 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-05-26Not applicableUs
Oxaprozintablet600 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2002-01-03Not applicableUs
Oxaprozintablet600 mg/1oralAv Kare, Inc.2014-03-06Not applicableUs
Oxaprozintablet, film coated600 mg/1oralPreferred Pharmaceuticals, Inc2012-02-14Not applicableUs
Oxaprozintablet, film coated600 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-08Not applicableUs
Oxaprozintablet, film coated600 mg/1oralRebel Distributors Corp2010-09-08Not applicableUs
Oxaprozintablet600 mg/1oralCarilion Materials Management2001-01-31Not applicableUs
Oxaprozintablet, film coated600 mg/1oralDr. Reddy's Laboratories Limited2001-01-31Not applicableUs
Oxaprozintablet600 mg/1oralSTAT Rx USA LLC2001-01-31Not applicableUs
Oxaprozintablet600 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Oxaprozintablet600 mg/1oralPhysicians Total Care, Inc.2001-09-04Not applicableUs
Oxaprozintablet600 mg/1oralDIRECT RX2014-01-01Not applicableUs
Oxaprozintablet600 mg/1oralDispensing Solutions, Inc.2001-01-31Not applicableUs
Oxaprozintablet600 mg/1oralEon Labs, Inc.2001-01-31Not applicableUs
Oxaprozintablet, film coated600 mg/1oralH.J. Harkins Company, Inc.2001-01-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlvoNot Available
Daypro AltaNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxaprozin potassium
ThumbNot applicableDBSALT001452
Categories
UNIIMHJ80W9LRB
CAS number21256-18-8
WeightAverage: 293.3166
Monoisotopic: 293.105193351
Chemical FormulaC18H15NO3
InChI KeyInChIKey=OFPXSFXSNFPTHF-UHFFFAOYSA-N
InChI
InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
IUPAC Name
3-(diphenyl-1,3-oxazol-2-yl)propanoic acid
SMILES
OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 2,4,5-trisubstituted oxazoles. These are compounds containing an oxazole ring substituted at positions 2, 4 and 5 only. Oxazole is a five-membered aromatic heterocycle with one oxygen, one nitrogen, and three carbon atoms. Isomers include 1,2-oxazole and 1,3-oxazole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassOxazoles
Direct Parent2,4,5-trisubstituted oxazoles
Alternative Parents
Substituents
  • 2,4,5-trisubstituted 1,3-oxazole
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.
PharmacodynamicsOxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.
Mechanism of actionAnti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective NSAID, with a cell assay system showing lower COX-2 selectivity implying higher COX-1 selectivity.
Related Articles
AbsorptionOxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.
Volume of distribution
  • 11 to 17 L/70 kg
Protein binding>99.5% bound to albumin
Metabolism

Hepatic. Ester and ether glucuronide are the major conjugated metabolites of oxaprozin, and do not have significant pharmacologic activity.

Route of eliminationOxaprozin is expected to be excreted in human milk based on its physical-chemical properties; however, the amount of oxaprozin excreted in breast milk has not been evaluated. Approximately 95% of oxaprozin is metabolized by the liver. Approximately 5% of the oxaprozin dose is excreted unchanged in the urine. Sixty-five percent (65%) of the dose is excreted in the urine and 35% in the feces as metabolite. Biliary excretion of unchanged oxaprozin is a minor pathway. Several oxaprozin metabolites have been identified in human urine or feces.
Half life54.9 hours
ClearanceNot Available
ToxicityOral, mouse: LD50 = 1210 mg/kg; Oral, rabbit: LD50 = 172 mg/kg; Oral, rat: LD50 = 4470 mg/kg
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Oxaprozin Action PathwayDrug actionSMP00113
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9512
Caco-2 permeable-0.5255
P-glycoprotein substrateNon-substrate0.7938
P-glycoprotein inhibitor INon-inhibitor0.8801
P-glycoprotein inhibitor IINon-inhibitor0.9047
Renal organic cation transporterNon-inhibitor0.8467
CYP450 2C9 substrateNon-substrate0.7623
CYP450 2D6 substrateNon-substrate0.8163
CYP450 3A4 substrateNon-substrate0.5781
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9327
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.93
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6313
Ames testNon AMES toxic0.9191
CarcinogenicityNon-carcinogens0.9364
BiodegradationReady biodegradable0.6095
Rat acute toxicity1.8484 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9906
hERG inhibition (predictor II)Non-inhibitor0.9123
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Gd searle llc
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Caraco pharmaceutical laboratories ltd
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories
Packagers
Dosage forms
FormRouteStrength
Tabletoral600 mg
Tablet, film coatedoral600 mg/1
Tabletoral600 mg/1
Prices
Unit descriptionCostUnit
Daypro 600 mg tablet2.98USD tablet
Daypro 600 mg caplet2.87USD caplet
Oxaprozin 600 mg tablet1.54USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6030643 No1997-05-162017-05-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point158-159 °CNot Available
water solubilityInsolubleNot Available
logP4.19HANSCH,C ET AL. (1995)
pKa4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0325 mg/mLALOGPS
logP3.33ALOGPS
logP3.46ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.95ChemAxon
pKa (Strongest Basic)-0.59ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.33 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity81.88 m3·mol-1ChemAxon
Polarizability31.69 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference
  1. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. Pubmed
General References
  1. Heller B, Tarricone R: Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Curr Med Res Opin. 2004 Aug;20(8):1279-90. [PubMed:15324531 ]
External Links
ATC CodesM01AE12
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (47 KB)
MSDSDownload (63.1 KB)
Interactions
Drug Interactions
Drug
AbciximabOxaprozin may increase the anticoagulant activities of Abciximab.
AcenocoumarolOxaprozin may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Acetylsalicylic acid.
AliskirenOxaprozin may decrease the antihypertensive activities of Aliskiren.
AlteplaseOxaprozin may increase the anticoagulant activities of Alteplase.
AmikacinOxaprozin may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmitriptylineAmitriptyline may increase the antiplatelet activities of Oxaprozin.
AnistreplaseOxaprozin may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Apixaban.
ArbekacinOxaprozin may decrease the excretion rate of Arbekacin which could result in a lower serum level and potentially a reduction in efficacy.
BalsalazideOxaprozin may increase the nephrotoxic activities of Balsalazide.
Citric AcidOxaprozin may increase the anticoagulant activities of Citric Acid.
ColesevelamColesevelam can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CollagenaseThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Collagenase.
CyclosporineOxaprozin may increase the nephrotoxic activities of Cyclosporine.
Dabigatran etexilateOxaprozin may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinOxaprozin may increase the anticoagulant activities of Dalteparin.
DasatinibDasatinib may increase the anticoagulant activities of Oxaprozin.
DeferasiroxThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Deferasirox.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Deoxycholic Acid.
DesmopressinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Oxaprozin.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Oxaprozin.
DicoumarolOxaprozin may increase the anticoagulant activities of Dicoumarol.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Oxaprozin.
DrospirenoneOxaprozin may increase the hyperkalemic activities of Drospirenone.
Edetic AcidOxaprozin may increase the anticoagulant activities of Edetic Acid.
EnoxaparinOxaprozin may increase the anticoagulant activities of Enoxaparin.
EplerenoneOxaprozin may decrease the antihypertensive activities of Eplerenone.
Ethyl biscoumacetateOxaprozin may increase the anticoagulant activities of Ethyl biscoumacetate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Oxaprozin.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Oxaprozin.
Fondaparinux sodiumOxaprozin may increase the anticoagulant activities of Fondaparinux sodium.
FramycetinOxaprozin may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
GentamicinOxaprozin may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GlucosamineGlucosamine may increase the antiplatelet activities of Oxaprozin.
HaloperidolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.
HeparinOxaprozin may increase the anticoagulant activities of Heparin.
HydralazineOxaprozin may decrease the antihypertensive activities of Hydralazine.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Oxaprozin.
IcosapentThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Icosapent.
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Oxaprozin.
KanamycinOxaprozin may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Oxaprozin.
LimaprostLimaprost may increase the antiplatelet activities of Oxaprozin.
LithiumThe serum concentration of Lithium can be increased when it is combined with Oxaprozin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Oxaprozin.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Oxaprozin.
NadololOxaprozin may decrease the antihypertensive activities of Nadolol.
NeomycinOxaprozin may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NetilmicinOxaprozin may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
ObinutuzumabThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Obinutuzumab.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Homoharringtonine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Oxaprozin.
PamidronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pamidronate.
ParoxetineParoxetine may increase the antiplatelet activities of Oxaprozin.
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Oxaprozin.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Oxaprozin.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Oxaprozin.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Oxaprozin.
PhenindioneOxaprozin may increase the anticoagulant activities of Phenindione.
PhenprocoumonOxaprozin may increase the anticoagulant activities of Phenprocoumon.
PorfimerOxaprozin may increase the photosensitizing activities of Porfimer.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Oxaprozin.
ProbenecidThe serum concentration of Oxaprozin can be increased when it is combined with Probenecid.
ReteplaseOxaprozin may increase the anticoagulant activities of Reteplase.
RibostamycinOxaprozin may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RidogrelOxaprozin may increase the anticoagulant activities of Ridogrel.
RivaroxabanOxaprozin may increase the anticoagulant activities of Rivaroxaban.
SparfloxacinOxaprozin may increase the neuroexcitatory activities of Sparfloxacin.
SpectinomycinOxaprozin may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptokinaseOxaprozin may increase the anticoagulant activities of Streptokinase.
StreptomycinOxaprozin may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
SulodexideOxaprozin may increase the anticoagulant activities of Sulodexide.
TacrolimusOxaprozin may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Oxaprozin.
TenecteplaseOxaprozin may increase the anticoagulant activities of Tenecteplase.
TenofovirThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tenofovir.
TipranavirTipranavir may increase the antiplatelet activities of Oxaprozin.
TobramycinOxaprozin may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TorasemideOxaprozin may decrease the diuretic activities of Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tositumomab.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxaprozin.
TriamtereneOxaprozin may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxaprozin.
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Oxaprozin.
UrokinaseOxaprozin may increase the anticoagulant activities of Urokinase.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Oxaprozin.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Oxaprozin.
VenlafaxineVenlafaxine may increase the antiplatelet activities of Oxaprozin.
VerteporfinOxaprozin may increase the photosensitizing activities of Verteporfin.
Vitamin EVitamin E may increase the antiplatelet activities of Oxaprozin.
WarfarinOxaprozin may increase the anticoagulant activities of Warfarin.
Food Interactions
  • Take with food, usually once a day after breakfast. Food decreases the rate of absorption but not the amount absorbed. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6. [PubMed:9831331 ]
  2. Kean WF: Oxaprozin: kinetic and dynamic profile in the treatment of pain. Curr Med Res Opin. 2004 Aug;20(8):1275-7. [PubMed:15324530 ]
  3. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. [PubMed:19952416 ]
  4. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. doi: 10.1111/j.1476-5381.2009.00162.x. Epub 2009 Mar 26. [PubMed:19338579 ]
  5. Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60. [PubMed:17024689 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60. [PubMed:17024689 ]
  2. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y: Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998 Apr 17;347(1):87-94. [PubMed:9650852 ]
  3. Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6. [PubMed:9831331 ]
  4. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002 Jul;302(1):18-25. [PubMed:12065695 ]
  5. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. [PubMed:19952416 ]
  6. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. doi: 10.1111/j.1476-5381.2009.00162.x. Epub 2009 Mar 26. [PubMed:19338579 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23